{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:20:09Z","timestamp":1778901609057,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11739-022-02936-8","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T11:04:51Z","timestamp":1644404691000},"page":"2159-2165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding and co-managing medication treatment options for opioid use disorder"],"prefix":"10.1007","volume":"17","author":[{"given":"Abigail","family":"Kay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8882-8122","authenticated-orcid":false,"given":"Rachel","family":"Shmuts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"2936_CR1","unstructured":"American Society of Addiction Medicine Opioid Addiction 2016 facts and figures. https:\/\/www.asam.org\/docs\/default-source\/advocacy\/opioid-addiction-disease-facts-figures.pdf. Accessed 4 Jan 2018"},{"key":"2936_CR2","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2013.0098","author":"R Meyer","year":"2014","unstructured":"Meyer R, Patel AM, Rattana SK, Quock TP, Mody SH (2014) Prescription opioid abuse: a literature review of the clinical and economic burden in the United States. Popul Health Manag. https:\/\/doi.org\/10.1089\/pop.2013.0098 (published online December 12, 2014)","journal-title":"Popul Health Manag"},{"key":"2936_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/137020","author":"J Lee","year":"2015","unstructured":"Lee J, Kresina TF, Campopiano M, Lubran R, Clark HW (2015) Use of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary care. BioMed Res Int. https:\/\/doi.org\/10.1155\/2015\/137020","journal-title":"BioMed Res Int"},{"key":"2936_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/npp.2009.110","volume":"35","author":"G Koob","year":"2010","unstructured":"Koob G, Volkow N (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217\u2013238. https:\/\/doi.org\/10.1038\/npp.2009.110","journal-title":"Neuropsychopharmacology"},{"key":"2936_CR5","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1038\/ijo.2009.65","volume":"33","author":"H Zheng","year":"2009","unstructured":"Zheng H, Lenard N, Shin A et al (2009) Appetite control and energy balance regulation in the modern world: reward-driven brain overrides repletion signals. Int J Obes 33:S8\u2013S13. https:\/\/doi.org\/10.1038\/ijo.2009.65","journal-title":"Int J Obes"},{"issue":"6","key":"2936_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0009-9236(99)90090-5","volume":"65","author":"KR Dyer","year":"1999","unstructured":"Dyer KR, Foster DJR, White JM et al (1999) Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationship. Clin Pharmacol Ther 65(6):685\u2013694","journal-title":"Clin Pharmacol Ther"},{"key":"2936_CR7","unstructured":"Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. A treatment improvement protocol. TIP 43. US Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment. Revised 2017, pp 70\u201371. https:\/\/www.store.samhsa.gov\/shin\/content\/SMA12-4214\/SMA12-4214.pdf."},{"issue":"9","key":"2936_CR8","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1360-0443.2006.01512.x","volume":"101","author":"D Justo","year":"2006","unstructured":"Justo D, Gal-OZ A, Paran Y et al (2006) Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction 101(9):1333\u20131338","journal-title":"Addiction"},{"key":"2936_CR9","unstructured":"Methadone [package insert]. US Food and Drug Administration website. https:\/\/www.fda.gov\/media\/76020\/download. Accessed 8 Dec 2019"},{"issue":"3","key":"2936_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000441470","volume":"22","author":"G Gerra","year":"2016","unstructured":"Gerra G, Manfredini M, Somaini L, Maremmani I, Leonardi C, Donnini C (2016) Sexual dysfunction in men receiving methadone maintenance treatment: clinical history and psychobiological correlates. Eur Addict Res 22(3):163\u2013175","journal-title":"Eur Addict Res"},{"issue":"2","key":"2936_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1300\/J069v24n02_08","volume":"24","author":"R Brown","year":"2005","unstructured":"Brown R, Balousek S, Mundt M, Fleming M (2005) Methadone maintenance and male sexual dysfunction. J Addict Dis 24(2):91\u2013106","journal-title":"J Addict Dis"},{"key":"2936_CR12","first-page":"75","volume-title":"Therapy in sleep medicine","author":"AL Kay","year":"2012","unstructured":"Kay AL, Stober KR, Serota R et al (2012) Drug abuse, dependency, and withdrawal. In: Barkoukis TJ, Matheson JK, Ferber R, Doghramji K (eds) Therapy in sleep medicine. Elsevier, Philadelphia, p 75"},{"issue":"1","key":"2936_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jsmc.2013.10.003","volume":"9","author":"S Javaheri","year":"2014","unstructured":"Javaheri S, Randerath WJ (2014) Opioid-induced central sleep apnea: mechanisms and therapies. Sleep Med Clin 9(1):49\u201356","journal-title":"Sleep Med Clin"},{"key":"2936_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","volume":"50","author":"A Ferrari","year":"2004","unstructured":"Ferrari A, Coccia CPR, Bertolini A et al (2004) Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 50:551\u2013555","journal-title":"Pharmacol Res"},{"key":"2936_CR15","first-page":"588","volume":"152","author":"JE Zweben","year":"1990","unstructured":"Zweben JE, Payte JT (1990) Methadone maintenance in the treatment of opioid dependence\u2014a current perspective, in addiction medicine [special issue]. West J Med 152:588\u2013599","journal-title":"West J Med"},{"issue":"3","key":"2936_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jama.293.3.297","volume":"293","author":"TJ Cicero","year":"2005","unstructured":"Cicero TJ, Inciardi JA (2005) Diversion and abuse of methadone prescribed for pain management. JAMA 293(3):293\u2013298. https:\/\/doi.org\/10.1001\/jama.293.3.297","journal-title":"JAMA"},{"key":"2936_CR17","unstructured":"https:\/\/www.gpo.gov\/fdsys\/pkg\/CFR-2002-title42-vol1\/pdf\/CFR-2002-title42-vol1-sec8-12.pdf. Accessed 1 Jan 2018"},{"issue":"4","key":"2936_CR18","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/00002508-200207001-00003","volume":"18","author":"EC Strain","year":"2002","unstructured":"Strain EC (2002) Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain 18(4):S14\u2013S27","journal-title":"Clin J Pain"},{"key":"2936_CR19","unstructured":"https:\/\/www.vivitrol.com\/content\/pdfs\/medication-guide.pdf. Accessed 16 Dec 2017 at 11:54."},{"issue":"7","key":"2936_CR20","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/cid\/ciaa105)","volume":"71","author":"ES Rosenthal","year":"2020","unstructured":"Rosenthal ES, Silk R, Mathur P et al (2020) Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs. Clin Infect Dis 71(7):1715\u20131722. https:\/\/doi.org\/10.1093\/cid\/ciaa105)","journal-title":"Clin Infect Dis"},{"key":"2936_CR21","doi-asserted-by":"publisher","unstructured":"Lee JD, Nunes EV, Novo P et al (2017) Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. www.thelancet.com. Published online November 14, 2017. https:\/\/doi.org\/10.1016\/S0140-6736(17)32812-x","DOI":"10.1016\/S0140-6736(17)32812-x"},{"key":"2936_CR22","unstructured":"https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm587312.htm. Accessed 26 Dec 2017 at 15:00"},{"issue":"2, Supplement","key":"2936_CR23","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","volume":"70","author":"SL Walsh","year":"2003","unstructured":"Walsh SL, Eisenberg T (2003) The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alc Depend 70(2, Supplement):S13\u2013S27","journal-title":"Drug Alc Depend"},{"key":"2936_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/ADM.0b013e31806c9202","volume":"1","author":"A Cowan","year":"2007","unstructured":"Cowan A (2007) Buprenorphine: the basic pharmacology revisited. J Addict Med 1:68\u201372","journal-title":"J Addict Med"},{"issue":"5","key":"2936_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-200443050-00005","volume":"43","author":"DS Harris","year":"2004","unstructured":"Harris DS, Mendelssohn JE, Lin ET, Upton RA, Jones RT (2004) Pharmacokinetics and subjective effects of sublingual buprenorphine, alone, or in combination with naloxone. Clin Pharmacokinet 43(5):329\u2013340","journal-title":"Clin Pharmacokinet"},{"key":"2936_CR26","unstructured":"Substance Abuse and Mental Health Services Administration. Buprenorphine. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/treatment\/buprenorphine. Updated May 4, 2020"},{"key":"2936_CR27","unstructured":"Highlights of prescribing information for Suboxone[TM]. https:\/\/www.suboxone.com\/pdfs\/prescribing-information.pdf. Accessed 24 July 2020"},{"key":"2936_CR28","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2012.9591","author":"JW Childers","year":"2012","unstructured":"Childers JW, Arnold RM (2012) Treatment of pain in patients taking buprenorphine for opioid addiction. J Palliat Med. https:\/\/doi.org\/10.1089\/jpm.2012.9591","journal-title":"J Palliat Med"},{"issue":"1","key":"2936_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","volume":"19","author":"EF McCance-Katz","year":"2010","unstructured":"McCance-Katz EF, Sullivan L, Nallani S (2010) Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 19(1):4\u201316","journal-title":"Am J Addict"},{"key":"2936_CR30","unstructured":"http:\/\/www.naabt.org\/30_patient_limit.cfm. Accessed 3 Jan 2018"},{"key":"2936_CR31","unstructured":"https:\/\/www.samhsa.gov\/medication-assisted-treatment\/become-buprenorphine-waivered-practitioner\/new-practice-guidelines-faqs. Accessed 28 Oct 2021"},{"key":"2936_CR32","unstructured":"Clinical Guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series, No 40. Center for Substance Abuse Treatment. Substance Abuse and Mental health Services Administration (US). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64237\/#A72375. Accessed 2 Jan 2018"},{"issue":"2","key":"2936_CR33","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1183\/09031936.00120012","volume":"42","author":"RJ Farney","year":"2013","unstructured":"Farney RJ, McDonald AM, Boyle KM et al (2013) Sleep disordered breathing in patients receiving therapy with buprenorphine\/naloxone. Eur Respir J 42(2):394\u2013403","journal-title":"Eur Respir J"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-02936-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-022-02936-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-02936-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T13:42:12Z","timestamp":1664458932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-022-02936-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["2936"],"URL":"https:\/\/doi.org\/10.1007\/s11739-022-02936-8","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"24 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Abby Kay, MD, is paid by the American Association of Addiction Psychiatry, through a grant from SAMHSA, to teach an eight-hour course to become certified to prescribe buprenorphine. She is also part of a grant through SAMHSA to increase medical student training on buprenorphine at the Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, Pennsylvania, USA. Rachel Shmuts, DO, and Melanie Beck, DO, have no conflicts of interest regarding the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"For this type of publication, formal consent is not required as no human subjects were involved.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}